One To Watch

Centessa Pharmaceuticals

A clinical-stage biopharmaceutical company focused on developing orexin receptor 2 agonists for sleep-wake disorders including narcolepsy and idiopathic hypersomnia.

Company Overview

A clinical-stage biopharmaceutical company focused on developing orexin receptor 2 agonists for sleep-wake disorders including narcolepsy and idiopathic hypersomnia. Centessa operates with a mission to discover and develop transformational medicines for patients with high unmet medical needs, concentrating primarily on neuroscience applications. The company has positioned itself as a potential leader in the sleep medicine space through its targeted approach to orexin pathway modulation.

Headquarters and Global Presence

Centessa is headquartered in Altrincham, Cheshire, United Kingdom, with additional operations in Cambridge, Massachusetts. The company maintains a transatlantic presence to support its drug development activities across both European and North American markets.

Founding and History

Founded in October 2020, Centessa Pharmaceuticals went public on May 28, 2021, establishing itself as a novel force in the biopharmaceutical landscape. The company adopted a pioneering "hub-and-spoke" model aimed at redefining drug development approaches. In March 2026, Eli Lilly announced its acquisition of Centessa for $6.3 billion to expand its neuroscience portfolio into sleep medicine.

Therapy Areas and Focus

Centessa focuses primarily on sleep-wake disorders within the broader neuroscience therapeutic area. The company targets specific conditions including narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia, representing rare neurological conditions with significant unmet medical needs. Beyond sleep disorders, the company has expressed interest in expanding into other neurological and neurodegenerative applications of orexin pathway modulation.

Technology Platforms and Modalities

The company's scientific approach centers on orexin receptor 2 (OX2R) agonist development, targeting the orexin/hypocretin system that regulates sleep-wake cycles and arousal. Centessa develops potential best-in-class oral therapeutics designed to restore normal sleep-wake function in patients with orexin pathway deficiencies. This mechanism addresses the underlying neurobiological cause of certain sleep disorders rather than merely treating symptoms.

Key Pipeline and Programs

Centessa's lead program centers on ORX750 and related OX2R agonists intended for oral administration across multiple sleep-wake disorders. The pipeline includes compounds in various stages of development targeting narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia. The company's orexin agonist portfolio represents potential first-in-class or best-in-class therapeutic opportunities in an underserved patient population.

Key Personnel

Mario Alberto Accardi serves as Chief Executive Officer and Director, leading the company's strategic direction and development programs. Stephen Kanes serves as Head of R&D, overseeing the company's neuroscience-focused drug development activities.

Strategic Partnerships

Centessa's OX2R agonist pipeline was jointly discovered in collaboration with Nxera Pharma, which retains a material economic interest in future development and commercialization. The pending acquisition by Eli Lilly represents the company's most significant strategic relationship, positioning Centessa's sleep medicine portfolio within Lilly's broader neuroscience capabilities.

FAQ Section

The company's future depends on successfully developing orexin receptor 2 agonists that can demonstrate meaningful clinical efficacy in sleep-wake disorders, particularly given the limited treatment options currently available for narcolepsy and idiopathic hypersomnia patients. With Lilly's acquisition pending, integration success and continued development momentum will be critical.

Orexin neurons regulate sleep-wake cycles and arousal, and their dysfunction or loss is directly implicated in narcolepsy and other sleep-wake disorders. OX2R agonists can potentially restore normal orexin signaling, addressing the root neurobiological cause rather than just managing symptoms with stimulants or other symptomatic treatments.

Centessa focuses specifically on orally bioavailable orexin receptor 2 agonists designed to be best-in-class, targeting the underlying orexin pathway deficiency in sleep-wake disorders. This mechanism-based approach differs from existing symptomatic treatments and represents a potentially transformational therapeutic strategy for patients with limited current options.

ORX750 represents Centessa's lead orexin receptor 2 agonist with potential best-in-class characteristics for treating narcolepsy and idiopathic hypersomnia. The program demonstrates the company's core competency in orexin pathway modulation and serves as the foundation for its broader sleep-wake disorder portfolio.

Sleep-wake disorders represent Centessa's primary therapeutic focus, specifically narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia. The company also explores broader applications of orexin receptor modulation in other neurological and neurodegenerative conditions within the neuroscience space.

Centessa operates as a clinical-stage biopharmaceutical company with orexin receptor 2 agonist programs spanning discovery through clinical development phases. The company's lead programs are advancing through clinical testing for sleep-wake disorder applications.

Key near-term factors to monitor include:

Clinical trial progress and efficacy data for ORX750 and related orexin agonists
Successful integration with Eli Lilly following the $6.3 billion acquisition
Competitive developments in sleep medicine, particularly from Takeda and Eisai
Regulatory pathway clarity for orexin receptor agonists in sleep-wake disorders

Want to Update your Company's Profile?